Sarepta Therapeutics Inc SRPT shares jumped up over 17 percent during Wednesday’s after-hours trading sessions, after the medical research and drug development company crushed earnings estimates.
A Closer Look At Q2 Earnings
- Revenue: $35 million (consensus estimate was $22.3 million)
- Adjusted Losses: $0.46 per share (was $1.19 per share last year)
- Guidance: Raised to $125 million–$130 million (was $95 million)
After Nomura managing director Christopher Marai spoke to new CEO Doug Ingram following the earnings call, he also highlighted a positive view on Sarepta’s future similar to Ingram’s March 1 invitation theses. Marai maintains his Buy rating and set an $84 price target.
According to TipRanks, eight analysts are averaging a strong buy rating and a price target of $66 on Sarepta. Shares of Sarepta were trading at $40.20 during Thursday’s pre-market session, and at time of publication, shares were up 21.01 percent at $41.24.
To read the latest and exclusive financial news, visit the Benzinga Pro news wire.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
